OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial
Hongxing Pan, Qianhui Wu, Gang Zeng, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 72
Hongxing Pan, Qianhui Wu, Gang Zeng, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 72
Showing 1-25 of 72 citing articles:
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
Sue Ann Costa Clemens, Lily Yin Weckx, Ralf Clemens, et al.
The Lancet (2022) Vol. 399, Iss. 10324, pp. 521-529
Open Access | Times Cited: 403
Sue Ann Costa Clemens, Lily Yin Weckx, Ralf Clemens, et al.
The Lancet (2022) Vol. 399, Iss. 10324, pp. 521-529
Open Access | Times Cited: 403
Considerations in boosting COVID-19 vaccine immune responses
Philip R. Krause, Thomas R. Fleming, Richard Peto, et al.
The Lancet (2021) Vol. 398, Iss. 10308, pp. 1377-1380
Open Access | Times Cited: 352
Philip R. Krause, Thomas R. Fleming, Richard Peto, et al.
The Lancet (2021) Vol. 398, Iss. 10308, pp. 1377-1380
Open Access | Times Cited: 352
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
The Lancet Microbe (2021) Vol. 3, Iss. 1, pp. e52-e61
Open Access | Times Cited: 340
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
The Lancet Microbe (2021) Vol. 3, Iss. 1, pp. e52-e61
Open Access | Times Cited: 340
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
Gary R. McLean, Jeremy P. Kamil, Benhur Lee, et al.
mBio (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 174
Gary R. McLean, Jeremy P. Kamil, Benhur Lee, et al.
mBio (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 174
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID ‐19 vaccines in Hong Kong
Chris Ka Pun Mok, Carolyn A. Cohen, Samuel M. S. Cheng, et al.
Respirology (2021) Vol. 27, Iss. 4, pp. 301-310
Open Access | Times Cited: 149
Chris Ka Pun Mok, Carolyn A. Cohen, Samuel M. S. Cheng, et al.
Respirology (2021) Vol. 27, Iss. 4, pp. 301-310
Open Access | Times Cited: 149
COVID-19 Vaccine Booster: To Boost or Not to Boost
Rahul Shekhar, Ishan Garg, Suman Pal, et al.
Infectious Disease Reports (2021) Vol. 13, Iss. 4, pp. 924-929
Open Access | Times Cited: 104
Rahul Shekhar, Ishan Garg, Suman Pal, et al.
Infectious Disease Reports (2021) Vol. 13, Iss. 4, pp. 924-929
Open Access | Times Cited: 104
Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
Sitthichai Kanokudom, Suvichada Assawakosri, Nungruthai Suntronwong, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 86-86
Open Access | Times Cited: 85
Sitthichai Kanokudom, Suvichada Assawakosri, Nungruthai Suntronwong, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 86-86
Open Access | Times Cited: 85
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
Jing Lian Suah, Masliyana Husin, Peter Seah Keng Tok, et al.
International Journal of Infectious Diseases (2022) Vol. 119, pp. 69-76
Open Access | Times Cited: 67
Jing Lian Suah, Masliyana Husin, Peter Seah Keng Tok, et al.
International Journal of Infectious Diseases (2022) Vol. 119, pp. 69-76
Open Access | Times Cited: 67
Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile
Susan M. Bueno, Katia Abarca, Pablo A. González, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e792-e804
Open Access | Times Cited: 99
Susan M. Bueno, Katia Abarca, Pablo A. González, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e792-e804
Open Access | Times Cited: 99
Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern
Jingwen Ai, Haocheng Zhang, Qiran Zhang, et al.
Cell Research (2021) Vol. 32, Iss. 1, pp. 103-106
Open Access | Times Cited: 91
Jingwen Ai, Haocheng Zhang, Qiran Zhang, et al.
Cell Research (2021) Vol. 32, Iss. 1, pp. 103-106
Open Access | Times Cited: 91
COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly
Piotr Rzymski, Carlos A. Camargo, Andrzej Fal, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1299-1299
Open Access | Times Cited: 76
Piotr Rzymski, Carlos A. Camargo, Andrzej Fal, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1299-1299
Open Access | Times Cited: 76
Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
Ritthideach Yorsaeng, Nungruthai Suntronwong, Harit Phowatthanasathian, et al.
Vaccine (2021) Vol. 40, Iss. 3, pp. 524-530
Open Access | Times Cited: 55
Ritthideach Yorsaeng, Nungruthai Suntronwong, Harit Phowatthanasathian, et al.
Vaccine (2021) Vol. 40, Iss. 3, pp. 524-530
Open Access | Times Cited: 55
Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021
Shirley L. L. Kwok, Samuel M. S. Cheng, Jennifer NS Leung, et al.
Eurosurveillance (2022) Vol. 27, Iss. 2
Open Access | Times Cited: 42
Shirley L. L. Kwok, Samuel M. S. Cheng, Jennifer NS Leung, et al.
Eurosurveillance (2022) Vol. 27, Iss. 2
Open Access | Times Cited: 42
A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern
Bárbara M. Schultz, Felipe Melo-González, Luisa F. Duarte, et al.
mBio (2022) Vol. 13, Iss. 4
Open Access | Times Cited: 42
Bárbara M. Schultz, Felipe Melo-González, Luisa F. Duarte, et al.
mBio (2022) Vol. 13, Iss. 4
Open Access | Times Cited: 42
A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
Kang Wang, Yunlong Cao, Yunjiao Zhou, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 46
Kang Wang, Yunlong Cao, Yunjiao Zhou, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 46
Cost‐effectiveness of COVID‐19 vaccination: A systematic review
Yaqun Fu, Jingyu Zhao, Peien Han, et al.
Journal of Evidence-Based Medicine (2023) Vol. 16, Iss. 2, pp. 152-165
Open Access | Times Cited: 20
Yaqun Fu, Jingyu Zhao, Peien Han, et al.
Journal of Evidence-Based Medicine (2023) Vol. 16, Iss. 2, pp. 152-165
Open Access | Times Cited: 20
A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Minjie Li, Juan Yang, Lin Wang, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 37
Minjie Li, Juan Yang, Lin Wang, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 37
Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects
Jiaqi Zhang, Shan Xing, Dan Liang, et al.
Frontiers in Cellular and Infection Microbiology (2021) Vol. 11
Open Access | Times Cited: 33
Jiaqi Zhang, Shan Xing, Dan Liang, et al.
Frontiers in Cellular and Infection Microbiology (2021) Vol. 11
Open Access | Times Cited: 33
Heterologous prime-boost immunization with CoronaVac and Convidecia
Jingxin Li, Lihua Hou, Xiling Guo, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 32
Jingxin Li, Lihua Hou, Xiling Guo, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 32
Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review
Deniz Can Güven, Taha Koray Şahin, Saadettin Kılıçkap, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 28
Deniz Can Güven, Taha Koray Şahin, Saadettin Kılıçkap, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 28
Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
Xinhua Chen, Wei Wang, Xinghui Chen, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 21
Xinhua Chen, Wei Wang, Xinghui Chen, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 21
SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic
Yiming Shao, Yingqi Wu, Yi Feng, et al.
Frontiers of Medicine (2022) Vol. 16, Iss. 2, pp. 185-195
Open Access | Times Cited: 19
Yiming Shao, Yingqi Wu, Yi Feng, et al.
Frontiers of Medicine (2022) Vol. 16, Iss. 2, pp. 185-195
Open Access | Times Cited: 19
SARS-CoV-2 variants: levels of neutralisation required for protective immunity
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 26
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 26
Plasma metabolome and cytokine profile reveal glycylproline modulating antibody fading in convalescent COVID-19 patients
Zhu Yang, Di Wu, Shanxin Lu, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 34
Open Access | Times Cited: 16
Zhu Yang, Di Wu, Shanxin Lu, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 34
Open Access | Times Cited: 16
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 Vaccines in Hong Kong
Chris Ka Pun Mok, Carolyn A. Cohen, Samuel M. S. Cheng, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 21
Chris Ka Pun Mok, Carolyn A. Cohen, Samuel M. S. Cheng, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 21
